ubiquitome-logo-white-text
ubiquitome-logo-white-text

Thank you for your entries!


Freedom to Choose Grant Program has now closed

 

Grant Award Winners will be announced soon!

Unlock the Freedom to Choose

We are excited to announce the launch of our Freedom to Choose Grant Program, focused on informing the isothermal - real time PCR technology debate.

liberty16-web

Stay ahead of the curve with the mobile, real-time system PCR that fits in the palm of your hand.

Download_on_the_App_Store_Badge_US-UK_RGB_blk_092917

As a next generation platform developer, we are inspired by our peers working on next generation therapies and tools to combat some of the most challenging issues our world faces such as aging populations, rising rates of cancer and the impacts of climate change.

Recent global events have showcased isothermal amplification technologies potential advantages over real time PCR. Ubiquitome’s mobile devices support both isothermal and real time PCR applications, as well as melt curve analysis, all in a mobile device that can be taken wherever the point of need is. We believe having the full suite of capabilities in a single device is key.

Be it isothermal or real time PCR, in the lab or out in the field or all of the above with Ubiquitome’s Liberty platforms, you truly have the Freedom to Choose.

Isothermal PCR Graph

What is the Freedom to Choose Grant Program?

Under this program, three winners will get to prove why their preferred technology – isothermal or real time PCR or both – are better for their next generation application.

  • Three winners will be selected from the finalists and each will receive a Liberty16 (worth US$5,995 each).

  • Grant winners will be selected on the basis of scientific merit, originality, readiness and how meaningful unique capabilities of the company’s devices are to advancing your work.

 

Liberty16 at work

FAQs

 

Q: Why focus on both isothermal and real time PCR?

A: Each technology approach has attributes which suit different applications and contexts. We hope our competition helps to informs and educates the on-going technology debate, while having a little fun along the way!

 

Q: Who is eligible for the Program?

A: Life science researchers focused on next generation emerging therapies and tools application areas such as induced pluripotent stem cell therapies, CAR T-cell therapies and NGS are especially welcome in addition to more traditional pathogen and adventitious agent detection. Applications featuring melt-based capability for confirmation and multiplexing are also welcomed.

 

Q: Who is Ubiquitome?

A: We were founded in 2014 with a vision of gold standard testing for everyone, everywhere through mobile, cloud connected molecular testing platforms. We are a NIH RADx award winner and our groundbreaking Liberty16 and Liberty16 Pro devices recently received FDA EUAs in conjunction with the Yale School of Public Health SalivaDirectTM initiative. We are also certified to ISO 13485 (medical devices).

 

Liberty16

Apply here

Applying for the Freedom To Choose Grant Program is easy!

 

Write an abstract of 500 words maximum describing your planned work.

Submit you abstract to us by the deadline:
6 October 2023.

 

Please note the following important dates:
Application Deadline: 6 October 2023 
Winners Notification: 13 October 2023

Freedom to Choose Grant Program Terms and Conditions

Don't miss this opportunity to show your prowess and gain access to a groundbreaking tool that can enhance your work!

Apply now for the Freedom to Choose Grant Program and unlock the possibilities that the Liberty16 can offer.